Biological activity and hydroxy safflor yellow A content of intermediates in preparation of Safflower Injection

LIANG Meng-meng1,2 LI Shi-fei1 WANG Kai-hong1 ZHANG Li-wei1

(1.Key Laboratory of Chemical Biology and Molecular Engineering under Ministry of Education, Institute of Molecular Science, Shanxi University, Taiyuan, China 030006)
(2.Modern Research Center for Traditional Chinese Medicine, Taiyuan, China 030006)

【Abstract】In order to investigate the effect of various production processes on the quality of Safflower Injection, the biological activities of the intermediates were evaluated by measuring activated partial thromboplastin time (APTT) and adenosine diphosphate (ADP) induced platelet aggregation in vitro. Intermediates were produced by key processes, such as extraction, concentration, twice alcohol precipitation, water sedimentation and two sterilizations during the production of Safflower Injection. The content of main chemical components in intermediates was determined by HPLC. The results showed that with the advance of the preparation process of Safflower Injection, the inhibition of ADP-induced platelet aggregation rate of each intermediate decreased gradually, and the trend of extending APTT activity decreased first and then increased. Meanwhile, the content of hydroxy safflor yellow A (HSYA) was gradually lowered, the content of p-hydroxy-cinnamic acid was increased, and new chemical component p-hydroxybenzaldehyde was produced. In conclusion, sterilization played a key role in the biological activity and HSYA content of Safflower injection.

【Keywords】 Safflower Injection; hydroxy safflor yellow A; p-hydroxybenzaldehyde; p-hydroxy-cinnamic acid; platelet aggregation; activated partial thromboplastin time (APTT) ;

【DOI】

【Funds】 National Standardization of Chinese Medicine (ZYBZH-C-JIN-44) Key Research and Development Project of Shanxi Province (201603D3113008)

Download this article

    References

    [1] Zhou L J. 红花注射液的临床应用研究 [J]. Evaluation and analysis of drug-use in hospitals of China, 2017, 17 (5): 718 (in Chinese).

    [2] Wan X H, Qin Y L, Yan T. 红花注射液药理作用研究进展 [J]. Acta Chinese Medicine and Pharmacology, 2011, 39 (6): 109 (in Chinese).

    [3] Liu Q, Chen C, Dai Z, et al. Active ingredient identification and dose response relationship comparison for the safflower injection from different manufactures [J]. Chinese Journal of Pharmaceutical Analysis, 2012, 32 (7): 1 158 (in Chinese).

    [4] Jin M, Zang B X, Li J R, et al. 羟基红花黄色素A热稳定性的初步研究 [J]. China Journal of Chinese Materia Medica, 2003, 28 (12): 1 197 (in Chinese).

    [5] Yang X H, Wang D D, Zhu Y, et al. Recent research progress on hydroxy safflor yellow A [J]. Journal of Traditional Chinese Medicine University of Hunan, 2013, 33 (3): 102 (in Chinese).

    [6] Zhao J F, Liu J, Guo Y, et al. Chemical constituents from Safflower injection and their bioactivity [J]. China Journal of Chinese Materia Medica, 2014, 39 (16): 3 102 (in Chinese).

    [7] Jin M, Li J R, Wu W. Study on the antioxidative effect of Safflor Yellow [J]. China Journal of Chinese Materia Medica, 2014, 29 (5): 447 (in Chinese).

    [8] Sun Y, Xu D P, Qin Z, et al. Protective cerebrovascular effects of hydroxy safflor yellow A (HSYA) on ischemic stroke [J]. Eur J Pharmacol, 2018, 818 (1): 604.

    [9] Zhu H B, Zhang L, Wang Z H, et al. Therapeutic effects of hydroxy safflor yellow A on focal cerebral ischemic injury in rats and its primary mechanisms [J]. J Asian Nat Prod Re, 2005, 7 (4): 607.

    [10] Yoon J M, Cho M H, Park I E, et al. Thermal stability of the pigments hydroxy safflor yellow A, safflor yellow B, and precarthamin from Safflower (Carthamus tinctorius) [J]. Food Chem Toxicol, 2003, 68 (3): 839.

    [11] Kanehira T, Saito K. Stability of carthamin and saffor yellow B on silk powders under continuous irradiation of fluorescent or UVC light [J]. LWT-Food Sci Technol, 2001, 34 (2): 55.

    [12] Fan L, Pu R, Zhao H Y, et al. Stability and degradation of hydroxy safflor yellow A and anhydrosafflor yellow B in the Safflower Injection studied by HPLC-DAD-ESI-MSn [J]. J Chin Pharm Sci, 2011, 20 (1): 47.

    [13] Chinese Pharmacopoeia. Vol. Ⅰ [S]. 2015: 151 (in Chinese).

    [14] Chen C, Liu Q, Zhang Y, et al. Screening of bioactivity assay methods of safflower injection [J]. Chinese Journal of Pharmaceutical Analysis, 2013, 33 (1): 12 (in Chinese).

    [15] Wang K H, Li S F, Zhang L W, et al. In vitro anticoagulant activity and active components of Safflower Injection [J]. Molecules, 2018, 23 (1): 170.

    [16] Wang B S. 生物活性测定法用于活血化瘀类中药注射剂质量控制的研究 [D]. Beijing: Beijing University of Chinese Medicine, 2010 (in Chinese).

    [17] Liu Z F, Li P, Li G S, et al. The effect of the extracting from Carthamus tinctorius L. on platelet aggregation and thrombosis [J]. Pharmacology and Clinics of Chinese Materia Medica, 2000, 16 (6): 20 (in Chinese).

    [18] Zang B X, Jin M, Li J R. 羟基红花黄色素A抗凝作用的研究 [J]. Chinese Traditional and Herbal Drugs, 2007, 38 (5): 741 (in Chinese).

    [19] Qin S C, Liang W X, Wen X W, et al. Clinical efficacy of hydroxy safflor yellow A injection for acute ischemic stroke with blood stasis syndrome treated [J]. Chinese Journal of Experimental Traditional Medical Formulae, 2016, 22 (21): 157 (in Chinese).

    [20] Fan L, Pu R, Zhao H Y, et al. 红花抗ADP诱导的血小板聚集活性研究 [J]. China Journal of Chinese Materia Medica, 2011, 36 (9): 1 242 (in Chinese).

This Article

ISSN:1001-5302

CN: 11-2272/R

Vol 43, No. 24, Pages 4850-4854

December 2018

Downloads:0

Share
Article Outline

Abstract

  • 1 Materials
  • 2 Methods
  • 3 Results and discussion
  • 4 Conclusion
  • References